Clinical trial NCT00125346: Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Cystic Fibrosis
Keywords: Tobramycin Inhalation Powder
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-08-01
Enrollment: 98
Sex: ALL
Minimum age (years): 6
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: Lung infections are a chronic problem for patients with cystic fibrosis (CF). Some patients with CF may have a type of bacteria called Pseudomonas aeruginosa in their lungs that can cause infections or make their symptoms worse. Tobramycin inhalation solution (TOBI) is an approved antibiotic, which is inhaled directly into the lungs, and can be used to manage these infections. Tobramycin inhalation powder (TIP) is a new, experimental powder formulation of tobramycin that is inhaled directly into the lungs using a T-326 inhaler. The purpose of this research study is to determine if TIP is safe and effective when compared to placebo (a powder with no medicine) treatment.


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of cystic fibrosis patients with Pseudomonas aeruginosa infection.
* Male and female subjects between 6 and 21 years of age at the time of screening.
* FEV1 at screening must be between 25% and 80% of normal predicted values.

Exclusion Criteria:

* Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.

Primary outcomes:
measure: Forced expiratory volume in 1 second (FEV1) measured at week 1 and week 5.
Secondary outcomes:
measure: Time until first antipseudomonal antibiotic (an antibiotic used to treat bacteria of a certain type [the genus pseudomonas]) is used
measure: Relative changes in FEV1 % predicted for patients who received TIP starting at visit 1 and for patients who received placebo starting at week 9, compared to all subsequent visits.
measure: Relative change in FEV1 % predicted for patients who received placebo from week 5 to week 13
measure: Relative change in FEV1 % predicted for patients who received placebo (from the average of four assessments [weeks 1, 2, 5, and 9] to week 13)
measure: Change from baseline in susceptibility of pseudomonas to the antibiotic during the study measured at weeks 5, 9, 13, 17, 21, and 25, and change from baseline in quantity of pseudomonas found in sputum during the study measured at weeks 5, 9, 13, 17, 21,
Other outcomes:
Locations:
city: Mobile
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Alabama
city: Phoenix
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Arizona
city: Fresno
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: California
city: Long Beach
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: California
city: Los Angeles
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: California
city: Oakland
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: California
city: Sacramento
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: California
city: Orlando
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Florida
city: Pensacola
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Florida
city: Atlanta
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Georgia
city: Augusta
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Georgia
city: Chicago
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Illinois
city: Oak Lawn
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Illinois
city: Ann Arbor
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Michigan
city: New Hyde Park
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: New York
city: New York
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: New York
city: Valhalla
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: New York
city: Durham
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: North Carolina
city: Cleveland
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Ohio
city: Columbus
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Ohio
city: Oklahoma City
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Oklahoma
city: Philadelphia
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Pennsylvania
city: Charleston
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: South Carolina
city: Tyler
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Texas
city: Salt Lake City
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Utah
city: Morgantown
country: United States
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: West Virginia
city: Buenos Aires
country: Argentina
facility: For information on a site near you, call 1-800-244-7668 Option "2"
city: Cordoba
country: Argentina
facility: For information on a site near you, call 1-800-244-7668 Option "2"
city: Curitiba
country: Brazil
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: PR
city: Campinas
country: Brazil
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: San Paolo
city: Florianopolis
country: Brazil
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: SC
city: Varna
country: Bulgaria
facility: For information on a site near you, call 1-800-244-7668 Option "2"
city: Vancouver
country: Canada
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: British Columbia
city: Hamilton
country: Canada
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Ontario
city: Sainte-Foy
country: Canada
facility: For information on a site near you, call 1-800-244-7668 Option "2"
state: Quebec
city: Santiago
country: Chile
facility: For information on a site near you, call 1-800-244-7668 Option "2"
city: Viña del Mar
country: Chile
facility: For information on a site near you, call 1-800-244-7668 Option "2"
city: Vilnius
country: Lithuania
facility: For information on a site near you, call 1-800-244-7668 Option "2"
city: Mexico City
country: Mexico
facility: For information on a site near you, call 1-800-244-7668 Option "2"
city: Monterrey
country: Mexico
facility: For information on a site near you, call 1-800-244-7668 Option "2"
city: Tijuana
country: Mexico
facility: For information on a site near you, call 1-800-244-7668 Option "2"
Study officials:
References: